However, a more frequent dosing schedule leading to a sustained loss of the XPO1-NPM1c interaction may optimize the anti-leukemic activity of XPO1 inhibition therapy in NPM1c AML (Pianigiani et al., 2022). Here, XPO1 is linked to acute myeloid leukemia.